Insights
Insights From Our Experts
Articles
Global Shifts in Legislative Regulation Are Forcing Pharma Back to the Drawing Board : February 2021
In only a short time this year, the pharmaceutical industry is witnessing new regulations and legislative changes going into effect globally – and the growing pains are setting in. Between the new U.S. administration and E.U. Pharmaceutical Strategy, governmental entities…
BLOG: Population Health Leadership
Posted by
Dr. Richard Stefanacci on February 24, 20212/24/21
“Population health” is the result of pushing health systems to be clinically and financially responsible for their communities. This is a significant shift from simply being focused on the volume of services delivered within the hospital. The focus on population health represents a movement for pharma from…
Reinventing Launch: The Gold Standard Of Drug Commercialization
In a world that is rapidly changing, we must evolve beyond traditional strategies to create true impact for patients. EVERSANA's complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of…
The Crush: How Covid-19 Is Impacting Mature Brand Revenue & Long-Term Value
The impact of COVID is reverberating across all aspects of society and business. In the healthcare industry, hundreds of thousands of patients are not getting proper access to and utilization of therapies that can improve their…
Reimbursement May Be on the Way for Remote Therapeutic Monitoring
The American Medical Association (AMA) manages the procedure code set that physicians and other healthcare professionals use to identify the services for which they bill. These codes are commonly known as the CPT® code set, which…
Transforming Pharma With Industry-Leading Partnerships
EVERSANA is filling an influx of essential commercialization needs to overcome strained resources and support COVID-19 treatment launches. From groundbreaking treatments to long-overdue therapy improvements, there will be at least five new treatments headed to market…
Alternative Product Distribution Model: Where Agility Meets Profitability
Distributing innovative, life-altering therapies to patients is no small feat, and manufacturers shouldn’t settle for the status quo of an outdated, one-size-fits-all model. As you develop your channel strategy, consider how your distribution model can benefit…
Key Factors to Obtaining Reimbursement for Digital Therapeutics in the U.S.
Posted on February 4, 20212/4/21
While wellness apps have been successful in a direct-to-consumer model, many digital therapeutics (DTx) providers are working to obtain reimbursement from U.S. payers. In a heterogenous payer ecosystem, the key question is how to obtain broad…
A Paul Simms Favorite: EVERSANA makes the list for 2021 Predictions
“Imagine there was a third way … an equivalent to the Apple App Store in our industry … maybe that model could start working in pharma; and, in fact, it is.” For pharmaceutical influencer Paul Simms,…
Under the Biden Team & Beyond COVID … What Lies Ahead for Healthcare
Posted by
Dr. Richard Stefanacci on January 29, 20211/29/21
While the obvious healthcare focus for the new Biden/Harris Administration will be on controlling the COVID-19 pandemic, it’s a critical time to assess what lies beyond COVID for their attention. To gain a sense of what’s…